{
  "docId": "019de070-ff46-75e9-a6a2-27d0e899d3b8",
  "docSlug": "714b2223d61a474cc0c3d011e3fc18ab",
  "documentTitle": "Centessa | IPO Presentation Deck | 33 slides",
  "authorId": "centessa",
  "authorName": "Centessa Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7843866,
  "pageNumber": 21,
  "pageCount": 33,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The slide uses a split-column layout to contrast internal milestones with external competitive landscape.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-ff46-75e9-a6a2-27d0e899d3b8/21",
  "deckHref": "/decks/019de070-ff46-75e9-a6a2-27d0e899d3b8",
  "deckJsonHref": "/decks/019de070-ff46-75e9-a6a2-27d0e899d3b8.json",
  "deckAnchorHref": "/decks/019de070-ff46-75e9-a6a2-27d0e899d3b8#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.04,
        "y": 0.23
      },
      "kind": "list",
      "text": "Phase 2a multiple repeat dose study ongoing: 6mo study of monthly subq dosing of SerpinPC at 3 dose levels in severe HA & HB +/-inhibitors patients; 23 subjects enrolled; Primary Objective: Safety and tolerability; Secondary: PK; Exploratory: ABR",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2d7a39d3-6fd5-4f89-a55e-03dcccaa525a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.52,
        "y": 0.18
      },
      "kind": "list",
      "text": "COMPETITIVE LANDSCAPE",
      "attrs": null,
      "subkind": "comparison",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2e7ab629-7869-4303-9c0d-bc3183f4c0cf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.52,
        "y": 0.23
      },
      "kind": "list",
      "text": "Emicizumab (Roche) ~HA: Marketed; Concizumab (Novo Nordisk) ~HB: Phase 3; Fitusiran (Sanofi) ~HB: Phase 3; Valoctocogene roxaparvovec (BioMarin) ~HA: Phase 3; Fidanacogene elaparvovec (Pfizer/Spark) ~HB: Phase 3",
      "attrs": null,
      "subkind": "comparison",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7cb49ad1-9000-411c-ac12-c69789db302b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.04,
        "y": 0.8
      },
      "kind": "list",
      "text": "Mid-to-late 2022: Data from 12-month open label extension study",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "25e54fff-8167-436b-8a17-e5c68b6b5fbd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.04,
        "y": 0.7
      },
      "kind": "list",
      "text": "Mid-to-late 2021: Data from 24-week Phase 2a multiple repeat dose study",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d8c9a394-527b-4e02-bbc9-b9a16140c7bf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.04,
        "y": 0.18
      },
      "kind": "list",
      "text": "STATUS & UPCOMING MILESTONES",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fd822778-39c4-47e3-9dfe-8222f6ac3556",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.04,
        "y": 0.6
      },
      "kind": "list",
      "text": "Early-to-mid 2021: Start of 48-week open label extension study",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ff387cf4-2e17-4b8c-a6ec-084c46c00cba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "SerpinPC: Status and Competition",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a2e20d71-0987-4a73-9e14-6637a94f1920",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline-item",
      "slug": null,
      "matchId": "ff66ad44-223f-4449-b4c9-7472e4747dfa",
      "evidence": "Chronological milestones listed for internal development",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}